Key Points
- Director John Higuchi bought 40,000 shares at an average price of $2.03 on April 7 for a total of $81,200, bringing his direct holding to 203,797 shares — a 24.42% increase in his position.
- The stock is trading around $2.00 with a market cap of about $14.6M; Lipocine reported a quarterly EPS of ($0.34) vs. consensus ($0.60) and a revenue beat, but remains loss-making with very negative margins.
- Investor sentiment is mixed: institutional ownership is low (~9.11%), analysts' average rating is Hold (average target $15), and a shareholder litigation inquiry has been announced, adding legal risk.
Lipocine Inc. (NASDAQ:LPCN - Get Free Report) Director John Higuchi acquired 40,000 shares of the business's stock in a transaction dated Tuesday, April 7th. The stock was purchased at an average price of $2.03 per share, with a total value of $81,200.00. Following the completion of the acquisition, the director directly owned 203,797 shares in the company, valued at approximately $413,707.91. This represents a 24.42% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Lipocine Trading Up 3.1%
LPCN opened at $2.00 on Wednesday. Lipocine Inc. has a 12-month low of $1.81 and a 12-month high of $12.37. The stock has a 50-day moving average price of $7.93 and a 200-day moving average price of $5.77. The stock has a market capitalization of $14.60 million, a P/E ratio of -1.19 and a beta of 1.09.
Lipocine (NASDAQ:LPCN - Get Free Report) last posted its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.26. The firm had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.12 million. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%.
Institutional Trading of Lipocine
Several institutional investors and hedge funds have recently bought and sold shares of LPCN. Citadel Advisors LLC bought a new position in shares of Lipocine in the 3rd quarter worth approximately $41,000. Jane Street Group LLC bought a new position in shares of Lipocine in the 4th quarter worth approximately $85,000. Geode Capital Management LLC raised its position in shares of Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company's stock worth $502,000 after acquiring an additional 1,374 shares in the last quarter. Squadron Capital Management LLC bought a new position in shares of Lipocine in the 4th quarter worth approximately $4,256,000. Finally, Diadema Partners LP bought a new position in shares of Lipocine in the 4th quarter worth approximately $2,095,000. 9.11% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have commented on LPCN. HC Wainwright reissued a "neutral" rating on shares of Lipocine in a research note on Monday. Weiss Ratings reissued a "sell (d-)" rating on shares of Lipocine in a research note on Friday, March 27th. Finally, Wall Street Zen raised Lipocine from a "sell" rating to a "hold" rating in a research note on Sunday, March 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $15.00.
Check Out Our Latest Research Report on LPCN
More Lipocine News
Here are the key news stories impacting Lipocine this week:
- Positive Sentiment: Company insiders increased stakes — CEO Mahesh Patel bought 25,000 shares (~$2.03 avg) and director John W. Higuchi bought 123,000 shares, signaling insider confidence and providing buy-side support to the stock. Mahesh Patel Purchases 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock
- Neutral Sentiment: HC Wainwright updated models upward — the firm raised FY2026 and quarterly EPS forecasts (e.g., FY2026 to ($1.91) from ($2.27) and several quarter EPS revisions) but keeps a "Neutral" rating, an outcome that reduces downside in estimates but does not convert to an upgrade. MarketBeat summary of analyst estimates
- Neutral Sentiment: Recent quarterly results showed a revenue beat and narrower-than-expected EPS loss (reported ($0.34) vs consensus ($0.60)), which supports the revised analyst estimates but the company remains loss-making and small-cap volatility is high. MarketBeat financial summary
- Negative Sentiment: HC Wainwright appears to have reduced its stance in a separate report (MSN coverage) — any downgrade or more cautious wording from a specialist biotech/healthcare desk can prompt short-term selling in a low-float name like LPCN. HC Wainwright & Co. downgrades Lipocine (LPCN)
- Negative Sentiment: Shareholder litigation inquiry — Johnson Fistel announced an investigation into potential claims involving Lipocine executives; legal risk and potential costs can weigh on sentiment and valuation. Johnson Fistel investigation announcement
Lipocine Company Profile
(
Get Free Report)
Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company's core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.
The company's lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
